- Home
- RAND vs COEP Comparison
RAND vs COEP Comparison
Compare RAND & COEP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RAND | COEP |
|---|---|---|
| Founded | 1969 | 2017 |
| Country | United States | United States |
| Employees | N/A | 7 |
| Industry | Finance: Consumer Services | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 32.4M | 72.7M |
| IPO Year | 1996 | N/A |
Fundamental Metrics
Financial Performance| Metric | RAND | COEP |
|---|---|---|
| Price | $11.57 | $12.00 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 4.2K | ★ 33.4K |
| Earning Date | 06-01-2026 | 01-01-0001 |
| Dividend Yield | ★ 10.21% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.05 | $6.32 |
| 52 Week High | $21.30 | $21.41 |
Technical Indicators
Market Signals| Indicator | RAND | COEP |
|---|---|---|
| Relative Strength Index (RSI) | 50.07 | 45.04 |
| Support Level | $10.31 | $11.76 |
| Resistance Level | $12.50 | $13.23 |
| Average True Range (ATR) | 0.49 | 0.90 |
| MACD | -0.00 | 0.05 |
| Stochastic Oscillator | 36.61 | 38.21 |
Price Performance
Historical ComparisonAbout RAND Rand Capital Corporation
Rand Capital Corp is a closed-end, externally managed, non-diversified investment company. The company's investment objective is to generate current income and, when possible, complement its current income with capital appreciation by focusing its debt and related equity investments in privately-held, lower middle market companies with committed and experienced managements in a broad variety of industries. It predominantly invests in higher-yielding debt instruments.
About COEP Coeptis Therapeutics Holdings Inc.
Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.